A share price of Aligos Therapeutics Inc [ALGS] is currently trading at $45.62, up 5.07%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ALGS shares have gain 10.86% over the last week, with a monthly amount glided 76.96%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aligos Therapeutics Inc [NASDAQ: ALGS] stock has seen the most recent analyst activity on August 19, 2024, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $75. Previously, Piper Sandler upgraded its rating to Overweight on January 06, 2023, and elevated its price target to $3. On January 06, 2023, upgrade upgraded it’s rating to Buy and revised its price target to $3 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $4 on March 23, 2022. JP Morgan downgraded its rating to a Neutral and reduced its price target to $12 on January 07, 2022. Jefferies downgraded its rating to Hold for this stock on January 06, 2022. In a note dated September 09, 2021, SVB Leerink initiated an Outperform rating and provided a target price of $29 on this stock.
Aligos Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $6.76 and $44.39. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Aligos Therapeutics Inc [NASDAQ: ALGS] shares were valued at $45.62 at the most recent close of the market. An investor can expect a potential drop of -93.42% based on the average ALGS price forecast.
Analyzing the ALGS fundamentals
Trailing Twelve Months sales for Aligos Therapeutics Inc [NASDAQ:ALGS] were 6.00M which represents -60.82% decline. Gross Profit Margin for this corporation currently stands at 0.66% with Operating Profit Margin at -15.77%, Pretax Profit Margin comes in at -12.79%, and Net Profit Margin reading is -12.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.87, Equity is -1.14 and Total Capital is -1.4. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.14.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 43.15 points at the first support level, and at 40.67 for the second support level. However, for the 1st resistance point, the stock is sitting at 47.45, and for the 2nd resistance point, it is at 49.27.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Aligos Therapeutics Inc [NASDAQ:ALGS] is 3.81. As well, the Quick Ratio is 3.81, while the Cash Ratio is 1.69. Considering the valuation of this stock, the price to sales ratio is 29.75, the price to book ratio is 3.03.
